Drug delivery system for relieving bone loss caused by leukemia
By constructing DSPE-PEG2k-E7 modified liposomes wrapped with LV-shSFRP1 lentivirus, targeted delivery of BMSCs is achieved, and the problem of reduced osteogenic differentiation caused by leukemia is solved, significantly improving bone density and bone mass, and reducing bone density and bone mass side effects of the drug.
Patent Information
- Application Number
- CN202411279389.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-11-26
AI Technical Summary
The mechanism of bone loss caused by leukemia is unclear, especially the reduction of osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) is an important mechanism of osteoporosis. It is difficult for the prior art to effectively target the delivery of RNAi-mediated targeted silencing of SFRP1 to promote Osteogenic differentiation of BMSCs.
By constructing a DSPE-PEG2k-E7 modified liposome wrapped with LV-shSFRP1 lentivirus, forming a shSFRP1@Lipo-E7 nanolipid drug-loading system, achieving specific targeted delivery of BMSCs, reducing SFRP1 expression, and promoting BMSCs osteogenesis Differentiation.
It significantly improved the utilization rate and circulation time of LV-shSFRP1 in BMSCs, significantly reduced the expression of SFRP1 in the bone tissues of B-ALL mice, improved bone density and bone mass, promoted new bone formation, and reduced drug regimens. Side effects of other cells.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention relates to the field of biopharmaceuticals, and in particular to a drug delivery system for alleviating bone loss caused by leukemia. Background Art
[0002] In recent years, the incidence of childhood tumors has been rising year by year, and childhood tumor-related bone loss, including osteopenia and osteoporosis, has gradually attracted people's attention. However, the mechanism of bone loss at the time of initial diagnosis of leukemia is still unclear.
[0003] Bone mesenchymal stem cells (BMSCs), as the main source of osteoblasts, play a key role in bone mass maintenance, bone homeostasis, and bone tissue regeneration. Leukemia cells can change the proliferation and osteogenic differentiation ability of BMSCs by "reprogramming" BMSCs. We have demonstrated through in vitro experiments that the osteogenic differentiation of B-ALL-derived BMSCs is reduced, so we speculate that the reduced osteogenic differentiation of BMSCs is one of the mechanisms of bone loss in children with leukemia.
[0004] Secreted frizzled-related protein 1 (SFRP1) is an inhibitor of the classic Wnt / βcatenin signaling pathway. The inhibitory effect of SFRP1 on the Wnt signaling pathway also plays an important role in the occurrence and development of bone-related diseases. When SFRP1 is highly expressed, the Wnt signaling pathway is inhibited, resulting in reduced osteogenic differentiation of BMSCs, which is an important mechanism leading to osteoporosis.
[0005] Lentivirus (LV)-shRNA-mediated RNAi gene silencing method has been widely used in clinical disease treatment, cancer screening, cancer treatment, treatment of rare neurological diseases and genetic diseases.
[0006] SFRP1, which is highly expressed in leukemia-derived BMSCs, is a key regulatory protein that mediates the reduction of BMSCs osteogenic differentiation. Our invention hopes to promote osteogenic differentiation of ALL-BMSCs by targeting and silencing the expression of SFRP1 in BMSCs through RNAi, thereby promoting bone formation in leukemia mice. Considering the timeliness and stability of the drug, we chose to construct a LV-shSFRP1 lentiviral vector to achieve in vivo silencing of SFRP1 expression in BMSCs of leukemia mice.
[0007] In order to better achieve the purpose of targeted knockout of SFRP1, maximize the bioavailability of the drug, and reduce off-target effects, an effective BMSCs targeted delivery system is essential.
[0008] Liposome (Lipo) is the most typical nano drug delivery carrier for drug delivery. Liposome is a closed artificial membrane vesicle composed of phospholipids and cholesterol. Liposome has good biocompatibility and can effectively mimic the cell membrane to play a membrane structure role, so that cells can effectively take up liposomes. Through the modification of liposomes, not only can the blood circulation time of the encapsulated drug be prolonged, but also the clearance of the drug by the circulation and immune system can be reduced. Through targeted modification, the drug can also be delivered to the target organ and target cell, so that the drug accumulates in specific tissues and cells, improves the distribution of the drug in the body, improves the bioavailability of the drug, enhances the effect of the drug, and reduces the side effects of the drug. Summary of the invention
[0009] In view of this, the present invention provides a drug delivery system for alleviating bone loss caused by leukemia. The present invention uses the E7 targeting peptide (DSPE-PEG2k-E7 (1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-Poly ethylene glycol-EPLQLKM) targeting MSCs to modify liposomes, and realizes the connection between DSPE-PEG2k-E7 and liposomes by combining DSPE with the phospholipid bilayer, and uses the modified liposomes to encapsulate the LV-shSFRP1 lentivirus, thereby constructing the shSFRP1@Lipo-E7 nanolipid drug delivery system with specific targeting to MSCs. Through shSFRP1@Lipo-E7, not only the targeted delivery of shSFRP1 is achieved, and the uptake rate of shSFRP1 by BMSCs in vivo is improved, but also the expression of SFRP1 in BMSCs can be knocked down, and the influence and side effects of shSFRP1 on other cells are reduced, further ensuring the biosafety of the drug delivery system.
[0010] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0011] The present invention provides the use of reducing the expression of SFRP1 gene in preparing a product for treating childhood acute lymphoblastic leukemia.
[0012] The present invention also provides a liposome drug delivery carrier, comprising: a polypeptide-modified liposome and a lentiviral vector; the lentiviral vector inhibits the expression of the SFRP1 gene.
[0013] In some embodiments of the present invention, the liposome in the above liposome drug delivery carrier is obtained by mixing hydrogenated soybean lecithin, cholesterol and octadecylamine.
[0014] In some embodiments of the present invention, the mass ratio of the hydrogenated soybean lecithin, the cholesterol and the octadecylamine in the liposome drug delivery carrier is 20:5:2.
[0015] In some embodiments of the present invention, the polypeptide in the above-mentioned liposome drug delivery carrier includes: E7 polypeptide.
[0016] In some embodiments of the present invention, the E7 polypeptide in the above-mentioned liposome drug delivery carrier includes: DSPE-PEG2K-E7.
[0017] The present invention also provides a method for preparing the above-mentioned liposome drug delivery carrier, comprising the following steps:
[0018] S1: in the presence of an organic solvent, mixing the liposome and the polypeptide to form a film, and hydrating the film to obtain the polypeptide-modified liposome;
[0019] S2: mixing the lentiviral vector with the polypeptide-modified liposome, ultrasonicating, and extruding to obtain the liposome drug delivery vector.
[0020] In some embodiments of the present invention, in the above preparation method, the virus titer of the lentiviral vector is 1×10 7 TU.
[0021] The present invention also provides the use of the above liposome drug delivery carrier and / or the liposome drug delivery carrier obtained by the above preparation method in any of the following items:
[0022] (I) Preparation of products for the treatment of childhood acute lymphoblastic leukemia; and / or
[0023] (II) preparing a product for promoting osteogenic differentiation of BMSCs; and / or
[0024] (III) preparing products for alleviating bone loss.
[0025] The present invention also provides a medicine, a preparation and / or a medicine combination, comprising the above liposome drug delivery carrier and / or the liposome drug delivery carrier obtained by the above preparation method and an acceptable adjuvant or auxiliary material.
[0026] The present invention combines E7 and PEG to achieve targeted modification of lipid delivery carriers. E7 modification promotes the capture and uptake of lipid carriers by BMSCs, and can deliver shSFRP1 or drugs to BMSCs in a targeted manner. shSFRP1@Lipo-E7 significantly reduced the expression of SFRP1 in the bone tissue of B-ALL mice, and the application of E7-modified liposomes significantly improved the utilization rate and circulation time of LV-shSFRP1 in BMSCs. shSFRP1@Lipo-E7 can significantly increase the bone density and bone mass of B-ALL mice, improve bone microstructure, and promote new bone formation. Therefore, shSFRP1@Lipo-E7 is a method for alleviating bone loss in leukemia mice with strong targeting, long duration, high bioavailability, and high safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0028] Figure 1 Comparison of osteogenic differentiation ability of hBMSCs from different sources in CON group and B-ALL group; a shows ALP staining at 7 days of osteogenic induction; b shows quantification of ALP activity at 7 days of osteogenic induction; c shows ARS staining at 21 days of osteogenic induction; d shows quantification of ARS staining at 21 days of osteogenic induction; n=3, * P<0.05, ** P < 0.01;
[0029] Figure 2 The volcano map a and cluster heat map b of differentially expressed proteins (Q8N474: SFRP1) are shown; red indicates up-regulated proteins, and blue indicates down-regulated proteins;
[0030] Figure 3 Figure 3 shows the effect of WAY316606 on osteogenic and adipogenic differentiation of hBMSCs derived from B-ALL; a shows WB detection of the expression of osteogenic-related proteins (ALP, COL1A1, OPN) in hBMSCs derived from B-ALL in the WAY-treated and untreated groups; bd shows quantitative analysis of osteogenic-related proteins; e shows ARS staining to observe calcium nodules; f shows ARS staining quantification; g shows Oil Red "O" staining to observe the formation of oil droplets after adipogenic differentiation; h shows Oil Red "O" staining quantification; WAY is the WAY316606-treated group, n=3, * P<0.05, **** P < 0.0001;
[0031] Figure 4Figure 2 shows the changes in bone mass in B-ALL mice. The femur was scanned with Micro-CT; a shows the three-dimensional reconstruction image of cancellous bone; b shows the two-dimensional reconstruction image of femur Micro-CT; c shows the analysis of bone parameters BMD, BV / TV, SMI, Tb / Th, Tb.Sp, Tb.N of mouse femur; n=6, *** P < 0.001, **** P < 0.0001);
[0032] Figure 5 Comparison of SFRP1 expression in trabecular bone between CON group and B-ALL group mice; a shows immunofluorescence staining of SFRP1 (red) in femurs of the two groups, blue is DAPI nuclear staining; b shows the quantitative results of immunofluorescence staining of SFRP1 in each group; n=3, *** P < 0.001;
[0033] Figure 6 Schematic diagram of the planar structure of shSFRP1@Lipo-E7 liposomes;
[0034] Figure 7 The morphology of Lipo, Lipo-E7 and shSFRP1@Lipo-E7 observed by transmission electron microscopy is shown;
[0035] Figure 8 Figure 2 shows the uptake of Lipo, Lipo-E7, and shSFRP1@Lipo-E7 by mBMSCs; a shows the uptake of various liposomes by mBMSCs; b shows the quantitative results of the uptake of various liposomes by mBMSCs; n=3, ns: not significant, **** P < 0.0001;
[0036] Fig. 9 The results showed that shSFRP1@Lipo-E7 reduced the expression of SFRP1 in the bone tissue of B-ALL mice; a showed the results of fluorescence staining of SFRP1 (red) in the femoral trabeculae of each group of mice, and blue was DAPI nuclear staining; b showed the quantitative results of SFRP1 immunofluorescence staining in each group; n=3, **P<0.01;
[0037] Fig.10 The results show that shSFRP1@Lipo-E7 can alleviate osteopenia in B-ALL mice; a shows a three-dimensional reconstruction image of femoral cancellous bone; b shows a two-dimensional reconstruction image of femur; c shows the analysis of bone parameters BMD, BV / TV, Tb / Th, Tb.N and SMI of mouse femur; n=5, * P<0.05, ** P<0.01, *** P < 0.001, ****P<0.0001. DETAILED DESCRIPTION
[0038] The invention discloses a drug delivery system for alleviating bone loss caused by leukemia.
[0039] It should be understood that the expression "one or more of..." includes each of the items recited after the expression individually and in various different combinations of two or more of the recited items, unless otherwise understood from the context and usage. The expression "and / or" in combination with three or more recited items should be understood to have the same meaning, unless otherwise understood from the context.
[0040] The use of the terms "comprising", "having" or "containing", including their grammatical synonyms, should generally be understood as open and non-restrictive, for example not excluding other unrecited elements or steps, unless otherwise specifically stated or otherwise understood from the context.
[0041] It should be understood that the order of steps or the order in which certain actions are performed is not important as long as the present invention remains operable. In addition, two or more steps or actions may be performed simultaneously.
[0042] The use of any and all examples or exemplary language, such as "for example" or "including", herein is intended only to better illustrate the invention and does not limit the scope of the invention unless otherwise claimed. No language in this specification should be construed as indicating that any non-claimed element is essential to the practice of the invention.
[0043] In addition, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values in the specific embodiments have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual test methods. Therefore, unless otherwise expressly stated, it should be understood that all ranges, quantities, values and percentages used in this disclosure are modified by "about". Here, "about" generally means that the actual value is within plus or minus 10%, 5%, 1% or 0.5% of a specific value or range.
[0044] In Preparation Example 1 to Preparation Example 2 and Example 1 to Example 6 of the present invention, the raw materials and reagents used can be purchased from the market.
[0045] The present invention will be further described below in conjunction with embodiments:
[0046] Preparation Example 1 Experimental Animals
[0047] In this part, 6-week-old female NSG mice were selected and divided into CON group (no treatment group), leukemia group (B-ALL group), leukemia + PBS group (B-ALL + PBS), and leukemia + material treatment group. According to the leukemia modeling group, each mouse was 1×10 6 The B-ALL mouse model was established by injecting human leukemia hB-ALL1 cells into the tail vein.
[0048] After 28 days of modeling, the femurs and tibias of 5 rats in the CON group and 5 rats in the B-ALL group were separated for extraction of BMSCs.
[0049] One week after the leukemia model mice were established, the leukemia + material treatment group was randomly divided into 6 groups, namely, B-ALL + Lipo group (simple Lipo treatment group), B-ALL + Lipo-E7 group (Lipo-E7 treatment group), B-ALL + NC group (simple free LV-NC treatment group), B-ALL + shSFRP1@Lipo-E7 group (shSFRP1@Lipo-E7 treatment group), B-ALL + NC@Lipo-E7 group (NC@Lipo-E7 treatment group), B-ALL + shSFRP1 group (simple free LV-shSFRP1 treatment group), and the corresponding 100 μL liposomes and lentivirus were injected through the tail vein, and the lentivirus was injected at 1×10 7 TU (Transducing-Units, TU, transduction unit)-100μL system; B-ALL+PBS group was given 100μL sterile PBS solution. After 3 weeks of feeding (4 weeks after leukemia modeling), 5 mice in each group were anesthetized and euthanized, and the femurs, serum, and solid organs of the mice were collected for the next experiment.
[0050] Preparation Example 2 Preparation and Characterization of Liposomes
[0051] 1. Preparation of liposomes by thin film hydration method
[0052] (1) Dissolve 20 mg of hydrogenated soybean lecithin, 5 mg of cholesterol, 2 mg of octadecylamine, and 2.76 mg of DSPE-PEG2k-E7 (Hangzhou Peptide Biotechnology Co., Ltd., AP17303) in 5 mL of chloroform.
[0053] (2) using a rotary evaporator to evaporate chloroform at a constant speed at 65°C to form a thin film;
[0054] (3) Add 6 mL of saline to hydrate the liposomes and divide into 3 portions, 2 mL each;
[0055] (4) Add 1×10 8TU LV-shSFRP1 (Jima Gene, 23116VZ), LV-NC, stirred for 2 h; the other part was directly stirred for 2 h to make Lipo-E7.
[0056] (5) After ultrasonic treatment for 15 min, the liposomes were extruded using 0.4 μm and 0.2 μm filters to produce shSFRP1@Lipo-E7, NC@Lipo-E7, and Lipo-E7 liposome nanoparticles.
[0057] (6) Store at 4°C for subsequent experiments.
[0058] Lipo preparation:
[0059] In step (1), DSPE-PEG2k-E7 was not added. In steps (2) and (3), the same steps were used as above. In step (4), lentivirus was not added during hydration.
[0060] 2. Transmission electron microscopy
[0061] (1) Negative staining of liposomes.
[0062] (2) Take a picture of it using a transmission electron microscope.
[0063] 3. Particle size and Zeta potential detection
[0064] (1) Preheat the machine for 30 minutes in advance.
[0065] (2) The particle size and Zeta potential of liposomes were detected using Zetasizer Advance instrument.
[0066] 4. Liposome DiO staining
[0067] (1) Pipette 500 μL of liposomes into a 1.5 mL EP tube, centrifuge at 12000 rpm for 10 min, discard the supernatant, and keep the liposome pellet;
[0068] (2) Prepare DiO staining solution according to the instructions;
[0069] (3) Add staining solution and stain at 37°C in the dark for 15 min.
[0070] (4) Wash twice with PBS and proceed with subsequent experiments.
[0071] 5. Verification of the targeting of shSFRP1@Lipo-E7 liposomes to mBMSCs
[0072] (1) Cells were cultured at 2×10 4 / well density in 24-well plates;
[0073] (2) After the cells adhered to the wall, DiO-stained shSFRP1@Lipo-E7 liposomes, Lipo, and Lipo-E7 were added and incubated in a dark incubator for 12 h;
[0074] (3) Discard the upper culture medium and wash the cells twice with PBS;
[0075] (4) Fix with 4% paraformaldehyde for 15 min and then stain with DAPI for 10 min;
[0076] (5) Place the sample under an inverted microscope with a magnification of 20 and observe and take photos.
[0077] Example 1
[0078] First, we induced osteogenic differentiation of BMSCs from children with newly diagnosed B-ALL and healthy children (CON group) and found that the osteogenic differentiation ability of BMSCs from children with leukemia was significantly lower than that of healthy children. Figure 1 , as shown in Table 1;
[0079] In order to study the osteogenic differentiation ability of B-ALL-derived BMSCs, we stained the cells with ALP after inducing hBMSCs osteogenic differentiation for 7 days. The results showed that compared with the CON group, the expression of ALP in hBMSCs in the B-ALL group was decreased ( Figure 1 ALP quantification also confirmed this result ( Figure 1 b). After inducing hBMSCs into osteogenesis for 21 days, we performed ARS staining on the cells. The results showed that after 21 days of osteogenesis induction, the formation of calcified nodules in the B-ALL group was reduced compared with the CON group ( Figure 1 c). ARS quantitative results showed that the calcium nodule content in the B-ALL group was 1.67 times less than that in the CON group ( Figure 1 d).
[0080] Table 1 Quantification results of ALP staining and Alizarin red staining of BMSCs in CON and B-AL groups after osteogenic induction
[0081]
[0082] Secondly, we performed proteomic sequencing on the two groups of BMSCs and found that the osteoblastic inhibitory protein SFRP1 was highly expressed in BMSCs of children with B-ALL, such as Figure 2 As shown in the figure, after using the SFRP1 inhibitor WAY316606 to inhibit SFRP1 function, the osteogenic differentiation ability of BMSCs in children with leukemia was enhanced, while the adipogenic ability was weakened. Figure 3 As shown in Table 2 and Table 3.
[0083] Table 2 Quantification of osteogenic-related protein expression in BMSCs of children with leukemia after inhibition of SFRP1 function using SFRP1 inhibitor WAY316606
[0084]
[0085] Table 3 Quantification results of BMSCs from children with leukemia after inhibiting SFRP1 function using the SFRP1 inhibitor WAY316606 after osteogenic Alizarin red staining and adipogenic Oil red O staining
[0086]
[0087] It was found that SFRP1 inhibits the osteogenic differentiation of BMSCs, which is one of the mechanisms of bone loss in children with leukemia.
[0088] Again, we established an acute B-lymphocytic leukemia mouse model and found that leukemia mice had bone loss, such as Figure 4 As shown in Figure 2, the expression of SFRP1 in the bone tissue and BMSCs of leukemia mice was significantly increased. Figure 5 ;
[0089] In order to analyze the bone mass and bone microstructure changes of B-ALL mice, the femurs of CON and B-ALL mice were scanned by Micro-CT 28 days after leukemia mice were established. The three-dimensional reconstruction results showed that ( Figure 4 and Table 4 ), compared with the CON group, the trabeculae under the growth plate of the B-ALL group were more disordered, the cancellous bone content was severely lost, and the bone marrow cavity space was enlarged ( Figure 4 a, 4b). Quantitative analysis of bone parameters showed that compared with the CON group, B-ALL mice had reduced bone mass, as shown by decreased BMD, BV / TV, Tb / Th, and Tb.N, and increased SMI and Tb.Sp ( Figure 4 c).
[0090] Table 4 Bone-related parameters of mice in the CON group and B-ALL group
[0091]
[0092] Example 2
[0093] In order to understand the expression of SFRP1 in bone tissue in vivo, we performed SFRP1 immunofluorescence staining on the femurs of the CON group and the B-ALL group mice with leukemia modeling for 4 weeks obtained in Example 1. The results showed that the expression of SFRP1 in the trabeculae under the femoral growth plate of the B-ALL group mice was significantly higher than that of the CON group ( Figure 5). Based on the distribution characteristics of SFRP1 expression in the femoral trabeculae of the two groups of mice, combined with the results of the number and volume of trabeculae shown by Micro-CT of the femurs of the two groups of mice, it can be preliminarily proved that SFRP1 expression is inversely proportional to the number and volume of trabeculae.
[0094] Example 3
[0095] Preparation Example 2 We used DSPE-PEG2K-E7 and liposomes (Liposome, Lipo) through thin film hydration method to construct a liposome drug delivery system that can target BMSCs and load shSFRP1 lentivirus (LV-shSFRP1), namely shSFRP1@Lipo-E7. This drug delivery system silences SFRP1 expression in BMSCs by delivering LV-shSFRP1 to BMSCs, promotes osteogenic differentiation of BMSCs, and alleviates bone loss in leukemia mice. Figure 7~Figure 10 shown.
[0096] The amphiphilic polymer bis-stearoylphosphatidylethanolamine polyethylene glycol (DSPE-PEG) has a strong tendency to form micelle structures in water, in which DSPE can bind to the phospholipid bilayer, thereby achieving the connection between DSPE-PEG-E7 and Lipo. Schematic diagram of the planar structure of shSFRP1@Lipo-E7 liposomes.
[0097] The shSFRP1@Lipo-E7 liposomes were observed by transmission electron microscopy, and the results showed that the liposomes had a spherical appearance of uniform size, and the modification of E7 and the encapsulation of lentivirus had no obvious effect on the morphology of the liposomes.
[0098] Example 4
[0099] In order to test the targeting of E7 peptide to BMSCs, we used DiO dye which shows green fluorescence to stain the liposome membrane. When the liposomes are taken up by cells, the DiO-labeled liposome membrane integrates into the cell membrane, and the cell membrane is labeled with green fluorescence, which can also reflect the cell uptake of liposomes. We used fluorescence microscopy to evaluate the uptake of different liposomes by ALL-mBMSCs. Figure 8 As shown in Table 5, the green fluorescence absorbed by the cells in the Lipo group (5.67%±0.47%) was significantly lower than that in the Lipo-E7 group (86.77%±1.61%) and the shSFRP1@Lipo-E7 group (84.82%±1.82%). The results showed that E7 modification could increase the affinity of liposomes for mBMSCs, and the loading of LV-shSFRP1 did not affect the affinity of liposomes for mBMSCs cells, nor did it affect the uptake of liposomes by BMSCs.
[0100] Table 5 Comparison of affinity of different liposomes to BMSCs
[0101]
[0102] Example 5
[0103] We further explored the effect of shSFRP1@Lipo-E7 intervention on SFRP1 expression in bone tissue of B-ALL mice. One week after leukemia modeling, we intervened leukemia mice by tail vein injection of PBS, Lipo, Lipo-E7, free LV-NC, shSFRP1@Lipo-E7, NC@Lipo-E7, and free LV-shSFRP1. Three weeks after intervention, we performed shSFRP1@Lipo-E7 intervention on the B-ALL+PBS group, B-ALL+Lipo group, B-ALL+Lipo-E7 group, B-ALL+NC@Lipo-E7 group, B-ALL+NC group, B-ALL+shSFRP1 group, and B-ALL+shSFRP1@Lipo-E7 group. The femurs of mice in the Lipo-E7 group were subjected to SFRP1 immunofluorescence staining. The results showed that compared with the B-ALL+PBS group, the expression of SFRP1 in the cancellous bone below the femoral growth plate of mice in the B-ALL+shSFRP1@Lipo-E7 group was significantly reduced; compared with the B-ALL+PBS group, there was no significant change in the expression of SFRP1 in the bone tissue of mice in the B-ALL+shSFRP1 group; compared with the B-ALL+shSFRP1 group, the expression of SFRP1 in the bone tissue of mice in the B-ALL+shSFRP1@Lipo-E7 group was reduced ( Fig. 9 a, 9b, Table 6).
[0104] Table 6 Immunofluorescence analysis of SFRP1 expression in femoral tissues of mice in each group
[0105]
[0106] The above experimental results show that the expression of SFRP1 in the bone tissue of B-ALL mice increases, and simple shSFRP1 intervention cannot knock down the expression of SFRP1, while shSFRP1@Lipo-E7 can effectively knock down the expression of SFRP in the bone tissue of B-ALL mice. At the same time, targeted delivery through E7 liposomes can effectively enhance the role of shSFRP1 in bone tissue.
[0107] Example 6
[0108] After demonstrating in Example 5 that shSFRP1@Lipo-E7 can knock out SFRP1 expression in trabecular bone in vivo, we performed Micro-CT scanning on the femoral specimens of each group of mice to analyze the changes in bone mass and bone microstructure of the femur of mice after knocking down SFRP1 expression in the bone tissue of B-ALL mice.
[0109] Micro-CT scanning analysis and three-dimensional reconstruction results showed that (1) compared with the B-ALL+PBS group and the B-ALL+NC@Lipo-E7 group, the uniformity of the trabeculae under the growth plate of B-ALL mice in the B-ALL+shSFRP1@Lipo-E7 group was increased, the loss of cancellous bone content was reduced, and the bone marrow cavity space was reduced ( Fig.10 a, 10b); (2) Compared with the shSFRP1 intervention group, the uniformity of the trabeculae under the growth plate of B-ALL mice after shSFRP1@Lipo-E7 intervention increased, the loss of cancellous bone content decreased, and the bone marrow cavity space decreased ( Fig.10 a, 10b); (3) Compared with the B-ALL+PBS group, the cancellous bone mass of B-ALL mice in the shSFRP1 intervention group did not increase significantly ( Fig.10 a, 10b); (4) Lipo alone, LV-NC, and Lipo+E7 intervention had no effect on the bone mass of B-ALL mice.
[0110] The bone-related parameters of mice in each group are shown in Table 7. The quantitative analysis results showed that compared with the B-ALL+PBS group, shSFRP1-treated group, and NC@Lipo-E7-treated group, shSFRP1@Lipo-E7 could effectively alleviate the bone loss of mice induced by B-ALL, as shown by increased BMD, BV / TV, Tb / Th, Tb.N, and decreased SMI ( Fig.10 c).
[0111] The results of bone mass and bone microarchitecture analysis showed that shSFRP1@Lipo-E7 could effectively improve the bone mass and bone microarchitecture of B-ALL mice. The application of Lipo-E7 can improve the bone loss caused by B-ALL by improving the bioavailability of LV-shSFRP1 in vivo.
[0112] Table 7 Bone-related parameters of mice in each group
[0113]
[0114] The present invention develops a drug delivery system with targeting to BMSCs, which delivers shRNA to BMSCs to knock out the expression of SFRP1 in BMSCs, improve the osteogenic differentiation function of BMSCs, and thus alleviate the biological effect of bone loss in leukemia mice.
[0115] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of reducing the expression of SFRP1 gene in the preparation of products for treating childhood acute lymphoblastic leukemia.
2. Liposome drug delivery carrier, It is characterized in that The invention comprises: a polypeptide-modified liposome and a lentiviral vector; the lentiviral vector inhibits the expression of the SFRP1 gene.
3. The liposome drug delivery carrier according to claim 2, It is characterized in that The liposome is obtained by mixing hydrogenated soybean lecithin, cholesterol and octadecylamine.
4. The liposome drug delivery carrier according to claim 3, It is characterized in that The mass ratio of the hydrogenated soybean lecithin, the cholesterol and the octadecylamine is 20:5:
2.
5. The liposome drug delivery carrier according to any one of claims 2 to 4, It is characterized in that The polypeptides include: E7 polypeptide.
6. The liposome drug delivery carrier according to claim 5, It is characterized in that The E7 polypeptide includes: DSPE-PEG2K-E7.
7. A method for preparing a liposome drug delivery carrier according to any one of claims 2 to 6, It is characterized in that The steps include: S1: in the presence of an organic solvent, mixing the liposome and the polypeptide to form a film, and hydrating the film to obtain the polypeptide-modified liposome; S2: mixing the lentiviral vector with the polypeptide-modified liposome, ultrasonicating, and extruding to obtain the liposome drug delivery vector.
8. The preparation method according to claim 7, It is characterized in that The viral titer of the lentiviral vector was 1×10 8 TU.
9. Use of the liposome drug delivery carrier according to any one of claims 2 to 6 and / or the liposome drug delivery carrier obtained by the preparation method according to claim 7 or 8 in any of the following items; (I) Preparation of products for the treatment of childhood acute lymphoblastic leukemia; and / or (II) preparing a product for promoting osteogenic differentiation of BMSCs; and / or (III) preparing products for alleviating bone loss.
10. Drugs, preparations and / or drug combinations, It is characterized in that The method comprises the liposome drug delivery carrier according to any one of claims 2 to 6 and / or the liposome drug delivery carrier obtained by the preparation method according to claim 7 or 8, and an acceptable auxiliary agent or excipient.
Citation Information
Cited By
Organic nano particle with high osteogenic performance as well as preparation method and application of organic nano particle
CN119564641A
